

Appl.No. 10/599,090
Amdt.dated March 28, 2008
Reply to Office action of January 31, 2008

REMARKS/ARGUMENTS

It is respectfully submitted that the drawings do show what is claimed. The phrases "increasing said dose size when the number of doses falling outside said predetermined tolerance exceeds a predetermined level" and "decreasing said dose size when the number of doses falling outside said predetermined tolerance is within a predetermined level" are shown in figure 1 as for example, the flow charts boxes containing "are more than 98% of well within tolerance" and "are less than 98% of well within tolerance". The drawings were of course as originally filed so there can be no new matter. In the event this disclosure is not deemed sufficient, the Examiner is respectfully requested to indicate in detail why such is not sufficient. There are no reference characters/numerals in the flow chart and hence there can be no failure to reference in the specification. A flow chart, while a drawing, is a textual description is Applicants' invention and thus forms part of the specification. Accordingly, it is believed to be compliant.

Claims 1-3 stand rejected under 35 U.S.C. §112, first paragraph as failing to comply with the written description requirement. As set forth above, the claim language draws directly from the written materials in the flow chart of claim 1 and hence are amply described.

Claims 1-3 stand rejected under 35 U.S.C. §112, second paragraph as being indefinite. It is submitted that standard industry terminology as understood by one of ordinary skill in the art at the time the invention was made, first and second components of material such as a resin and catalyst are dispensed. For a 1:1 material which requires equal parts of first and second components, one might (for a sequential dispensing apparatus) dispense first 25cc of the first material and then 25cc of the second material forming a dose of 50cc, the dose being the total of

Appl.No. 10/599,090
Amdt.dated March 28, 2008
Reply to Office action of January 31, 2008

the "slugs" of the first and second components. The claims reference the dose size so if the dose is cut in half, the component pieces of the dose would each be cut in half.

Applicant respectfully requests that a timely Notice of Allowance be issued in this case.

Respectfully submitted,



Douglas B. Farrow

Registration No. 28582

Graco Inc.

PO Box 1441

Minneapolis, MN 55440

(612) 623-6769

pto@graco.com

Attachments